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Abstract
Despite recent clinical guidelines recommending early initiation and widespread use of antiretroviral therapy
(ART), many HIV-infected individuals are not receiving ART—in particular low-income, minority substance
users. Few studies have examined psychological, as opposed to structural, factors related to not receiving ART in
this population. Perceived capacity to tolerate physical and psychological distress, known as distress tolerance
(DT), may be a particularly relevant yet understudied factor. The current study tested the relationship between
self-reported physical and psychological DT and ART receipt among predominantly low-income, minority HIV-
infected substance users (n = 77). Psychiatric disorders, biological indicators of health status, ART use, structural
barriers to health care, and self-reported physical and psychological DT were assessed. 61% of participants were
receiving ART. The only factors that distinguished individuals not on ART were greater avoidance of physical
discomfort, higher psychological DT, and higher CD4 count. Both DT measures remained associated with ART
use after controlling for CD4 count and were associated with almost a two-fold decrease in likelihood of ART
receipt. Current findings suggest higher perceived capacity to tolerate psychological distress and greater
avoidance of physical discomfort are important factors associated with lower ART use among substance users
and may be important intervention targets.
Introduction
Recent clinical guidelines recommend earlier initia-tion and more widespread antiretroviral therapy (ART)
use for optimal HIV/AIDS outcomes, with current recom-
mendations suggesting ART use for nearly all individuals
diagnosed with HIV, regardless of disease stage.1,2 ART use is
critical for viral suppression and slower disease progression
and may also slow HIV transmission to others.3 Yet, a recent
Centers for Disease Control and Prevention report estimated
that only 45% of individuals diagnosed with HIV are receiv-
ing ART.4 In particular, low-income, minority substance users
have consistently been identified as a high-risk group for not
receiving ART.5–7 Increasing the proportion of individuals
receiving ART, particularly in these high-risk groups, has
important implications for HIV treatment and prevention.
Although a great deal of empirical attention has been paid
to structural (e.g., transportation, cost) barriers to ART
receipt, there has been less research on equally important
psychological barriers (e.g., fear of side effects). This is despite
evidence from a recent survey that among a sample of patients
living with HIV/AIDS (n = 158), 82% reported psychological
barriers to receiving HIV treatment, including fear of physical
side effects, fear of other people knowing, and stigma, as
opposed to structural factors.8 Evidence indicates that pa-
tients face numerous forms of physical and psychological
distress when considering ART use.9,10 As such, individual
differences in one’s perceived capacity to cope with or tolerate
this distress may play an important role in predicting initia-
tion and continuation of ART. Psychosocial models of HIV
management recognize not only the disproportionate levels of
distress experienced by individuals living with HIV/AIDS
(e.g., related to living with a chronic condition, stigma, trau-
ma), but also how individuals’ response to distress is important
in predicting optimal management of HIV/AIDS; for in-
stance, previous research testing a stress coping model of HIV
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management among individuals on ART (n = 322) found that
greater avoidance in the face of negative affect predicted
worse HIV outcomes over a 15-month period.11
One construct that captures individual differences in re-
sponse to distress is distress tolerance (DT), conceptualized
either as one’s perceived capacity to withstand aversive
physical and psychological states (i.e., assessed via self-report
measures), or one’s ability to withstand behaviorally psy-
chological or physical distress (i.e., assessed via latency to
discontinuation of a distressing task).12,13 Both physical
and psychological DT have been conceptualized as multi-
dimensional constructs; physical DT reflects both one’s per-
ceived capacity to tolerate physical discomfort and tendency
to avoid physical discomfort,12 whereas psychological DT
encompasses one’s perceived tolerability of negative emo-
tional states, appraisal and acceptability of negative emotions,
levels of absorption by negative emotion, and capacity to
regulate negative emotion.13
The DT construct maps closely onto existing psychosocial
models of HIV management given the attention to perceived
capacity to tolerate both physical and psychological states.
Previous researchers have suggested the importance of exam-
ining DT in HIV management, as numerous stressors involved
with HIV treatment may contribute to psychological and
physical distress and perpetuate maladaptive coping responses
among individuals with low psychological DT.14 Regarding
the important outcome of ART receipt specifically, there are
numerous forms of physical (i.e., side effects) and psychologi-
cal (i.e., fear, stigma) distress associated with receiving ART. As
such, individual differences in perceived capacity for tolerating
such distress may distinguish individuals who delay ART re-
ceipt. Previous work in the area of HIV/AIDS has found a
relationship between low psychological DT and both ART
nonadherence and greater HIV symptom levels, such that in-
dividuals with lower psychological DT had greater ART non-
adherence and symptom levels.15 However, DT has not been
tested in relation to receipt of ART, only ART adherence, and
more fine-grained analyses of the multiple dimensions of DT
have not previously been examined in this relationship. In light
of the numerous forms of distress associated with being on
ART, this may be very relevant.
The current study aimed to expand upon existing stress
coping models of HIV management to focus specifically on
the construct of DT in order to improve our understanding of
potential psychological barriers to ART receipt. Specifically,
the current study tested the relationship between self-
reported capacity to tolerate both physical and psychological
distress and ART receipt among low-income, largely African
American substance using individuals living with HIV/
AIDS, a group at high risk for not receiving ART.5–7 Study
hypotheses included that lower levels of self-reported physi-
cal and psychological DT would be associated with lower
likelihood of ART receipt and that these associations would
remain significant above and beyond the variance accounted
for by other relevant factors that distinguish individuals
based on ART use, including demographic characteristics,
health status (CD4 count), and structural barriers to care.
Methods
Participants for the current study were recruited from a
large urban residential substance abuse treatment center.
Patients were referred by government agencies or mandated
to treatment by the court system. Patients were required to
have completed full detoxification and have a negative urine
drug screen upon admission to the treatment facility. Regular
urinalysis drug testing was conducted, and any substance use
was grounds for program dismissal. Medication assisted
therapy (MAT) was not provided at this treatment center (i.e.,
methadone, buprenorphine, vivitrol, or naltrexone for opioid
dependence and naltrexone, vivitrol, acamprosate, and di-
sulfiram for alcohol dependence).
Patients were recruited for the study after their first week in
treatment and before completion of their third week. Eighty
HIV-infected individuals were approached for participation;
of those, three declined participation. Patients were in sub-
stance abuse treatment for a mean of 14.11 days (S.D. = 8.67) at
the time of the study assessment. During this time period, all
patients in the facility received a standard intake interview
that included an assessment of medical history and medica-
tion use. Patients were eligible for participation if they self-
reported being HIV positive, which was also verified with
treatment center medical records. Eligible patients were pro-
vided detailed information about the study and those inter-
ested provided informed consent. The importance of
maintaining patient confidentiality and privacy was stressed
throughout the study screening session. Additionally, treat-
ment center staff members were not made aware of patients’
study participation or refusal, and participation in the study
did not affect patients’ status in treatment. All study proce-
dures were approved by the University Institutional Review
Board.
Participants were administered the Structured Clinical In-
terview for DSM-IV (SCID-I)16 that included an assessment of
current Axis I disorders, including all mood, anxiety, psy-
chotic, and substance use disorders (assessed for alcohol,
crack/cocaine, heroin, other opioid medications, cannabis,
sedatives, stimulants, hallucinogens, and poly substance use).
All Axis I disorders with greater than or equal to 5% preva-
lence in the sample were included in Table 1.
To assess biological measures of health status, participants’
CD4 count and viral load were obtained within a 3-month
window of the study assessment (mean = 9.57 days before;
S.D. = 30.35 days). Viral load was highly skewed (skew-
ness = 4.08, S.E. = 0.29) and as such was log10 transformed.
Structural barriers to health care were assessed using a 9-
item scale measuring access to care, including affordability,
convenience, and availability (higher scores indicate greater
access)17 and the patient-doctor relationship questionnaire
(PDRQ-9; higher scores indicate a more favorable patient-
doctor relationship).18 In addition to basic demographic in-
formation, participants self-reported years since HIV diag-
nosis, whether they had a primary care provider (PCP) and a
health insurance plan, and whether they were homeless prior
to substance abuse treatment entry. They also self-reported
whether they were currently receiving ART (yes/no) and/or
psychotropic medication, both of which were verified with
treatment center medical records.
Perceived capacity to tolerate physical distress was mea-
sured using the 5-item self-report Discomfort Intolerance
Scale (DIS),12 which measures individuals’ perceived capacity
to withstand uncomfortable but nonpainful bodily sensations.
The DIS has two subscales: (1) Intolerance of physical discom-
fort (e.g., ‘‘I can tolerate a great deal of physical discomfort’’);
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and (2) Avoidance of physical discomfort (e.g., ‘‘I take extreme
measures to avoid feeling physically uncomfortable’’). Higher
scores on the subscales indicate greater intolerance of physical
discomfort and greater avoidance of physical discomfort. In-
ternal consistency of both subscales in the current sample
were acceptable (Avoidance: a = 0.77; Intolerance: a = 0.73),
which is consistent with other studies that have used the DIS
in a similar population (i.e., among heavy substance us-
ers).19,20 To test specific relationships of the components of
self-reported physical DT and ART use, all analyses were
conducted using the separate subscales in line with previous
recommendations using the DIS.21
Perceived capacity to tolerate psychological distress was
assessed using the 15-item self-report Distress Tolerance Scale
(DTS),13 which assesses perceived ability to withstand nega-
tive emotional states. The DTS has four subscales: (1) Tolerance
of distress (e.g., ‘‘I can’t handle feeling distressed or upset’’);
(2) Appraisal of distress (e.g., ‘‘My feelings of distress or being
upset are not acceptable’’); (3) Absorption of attention by neg-
ative emotion (e.g., ‘‘When I feel distressed or upset, I cannot
help but concentrate on how bad the distress actually feels’’);
(4) Regulation efforts to alleviate distress (e.g., ‘‘When I feel
distressed or upset I must do something about it immediate-
ly’’). Higher scores on the subscales indicate greater perceived
capacity to tolerate psychological distress, less negative ap-
praisal of distress, less absorption by negative emotion, and
less need to immediately regulate distress. Internal consis-
tency of DTS subscales ranged from fair to acceptable in the
current sample (Tolerance: a = 0.75; Absorption: a = 0.75;
Regulation = 0.62; Appraisal = 0.68), which is consistent with
Table 1. Comparison of Groups on Demographic Variables, Psychopathology, Health Status,






(n = 30) Statistic p Value
Demographics
Age, mean (SD) 45.40 (7.92) 45.74 (7.83) 44.82 (8.18) t(75) = 0.49 0.63
Gender v2 (2) = 3.06 0.22
Male, % 41.33 48.94 28.57
Female, % 50.67 44.68 60.71
Transgender, % 8.00 6.38 10.71
Marital status v2 (2) = 1.22 0.54
Single, % 62.67 57.45 71.43
Separated/divorced, % 26.67 29.79 21.43
Married, % 9.33 10.64 7.14
Race v2 (3) = 3.48 0.32
White, % 1.33 2.13 0.00
Black, % 94.67 93.62 96.43
Hispanic, % 2.67 4.26 0.00
Native American, % 1.33 0.00 3.57
Heterosexual, % 73.00 73.91 71.43 v2 (2) = 0.09 0.96
£ High school/GED, % 78.67 78.72 78.57 v2 (1) = 0.00 0.99
Total annual income < $10,000, % 78.67 80.85 75.00 v2 (1) = 0.36 0.55
Unemployed, % 89.33 85.11 96.43 v2 (1) = 2.36 0.12
Has a PCP, % 95.95 97.83 92.86 v2 (1) = 1.11 0.29
Has a health insurance plan, % 93.24 95.65 89.29 v2 (1) = 1.12 0.29
Homeless, % 11.69 8.51 16.67 v2 (1) = 1.18 0.28
Prescribed psychotropic medication, % 51.32 46.81 58.62 v2 (1) = 1.00 0.32
Psychopathology*
PTSD, % 12.33 13.64 10.34 v2 (1) = 0.18 0.68
MDD, % 20.00 15.56 26.67 v2 (1) = 1.39 0.24
GAD, % 6.67 8.70 3.45 v2 (1) = 1.22 0.27
Bipolar I, % 14.47 10.87 20.00 v2 (1) = 0.79 0.38
Hal dependence (past year), % 6.49 10.64 0.00 v2 (1) = 3.41 0.07
Cannabis dependence (past year), % 6.67 6.67 6.67 v2 (1) = 0.00 0.99
Crack/cocaine dependence (past year), % 53.25 48.94 60.00 v2 (1) = 0.90 0.34
Alcohol dependence (past year), % 31.58 30.43 33.33 v2 (1) = 0.07 0.79
Opioid (heroin) dependence (past year), % 25.33 24.44 26.67 v2 (1) = 0.05 0.83
Health status
CD4 count, mean (SD) 491.21 (300.86) 442.36 (256.73) 573.21 (353.08) t(75) = - 1.89 0.06
Viral load (Log10), mean (SD) 2.46 (1.14) 1.97 (0.83) 3.67 (0.89) t(75) = - 7.37 0.0001
Years since HIV diagnosis, mean (SD) 10.30 (7.39) 10.74 (6.99) 9.11 (8.52) t(73) = .75 0.46
Structural barriers
Access to care, mean (SD) 75.60 (20.56) 78.47 (16.88) 70.88 (25.11) t(74) = 1.56 0.12
Patient–doctor relationship, mean (SD) 39.16 (7.43) 40.20 (6.49) 37.46 (8.62) t(74) = 1.55 0.13
*All current Axis I diagnosis with ‡ 5% prevalence in current sample are listed. GAD, generalized anxiety disorder; Hal, hallucinogen;
MDD, major depressive disorder; PCP, primary care physician; PTSD, post-traumatic stress disorder.
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other studies that have administered the DTS among largely
minority HIV positive substance users.14,15,22 To test specific
relationships of the components of self-reported psychological
DT and ART use, all analyses were conducted using the sep-
arate subscales, which is also in line with previous recom-
mendations.13
Statistical analyses overview
First, group status was determined based on ART use
status (yes/no), which was self-reported and verified with
treatment center medical records. Next, independent sam-
ples t-tests and chi square tests were used to compare the two
groups on demographic information, psychopathology,
health status (CD4 count and viral load, years living with
HIV and PCP status), structural barriers to care, patient–
doctor relationship, and self-reported physical and psycho-
logical DT. Any significant differences between groups on
demographic or clinical information were to be included as
covariates in subsequent analyses, which follow from sta-
tistical recommendations to select covariates based on rela-
tionships with the main outcome.23 As a conservative
approach to identify potential covariates, group differences
were assessed at p < 0.10. Group differences in the DT sub-
scales were also examined to determine which scales to use
as the independent variable (IV) in the model. To identify the
contribution of DT to ART receipt, a logistic regression
analysis was conducted with ART receipt as the dependent
variable (0 = ART use; 1 = no ART use), entering any group
differences in demographic or clinical information as cov-
ariates in the first step, and in the second step, entering any
relevant DT measures (i.e., subscales of the DIS or DTS) that
differed across groups.
Results
Of the final sample (n = 77), 94.7% were Black, 73% het-
erosexual, 50.7% women, 78.7% had less than or equal to a
high school degree or GED, and 78.7% had a total annual
income of less than $10,000. Regarding ART use, in total, 61%
(n = 47) of the sample was receiving ART and 39% (n = 30) was
not receiving ART. Individuals not receiving ART had slightly
higher CD4 counts (t(75) = - 1.89, p = 0.06) and higher viral
load (viral load (t(75) = - 7.37, p < 0.0001). Group differences
in viral load were not included as a covariate, as changes in
viral load are the direct biological consequence of ART; group
differences in viral load support credibility of the distinction
of the two groups. CD4 count was included as a covariate
in subsequent analyses. Regarding group differences in the
DT subscales, individuals not receiving ART had higher self-
reported avoidance of physical discomfort, (t(71) = - 2.19,
p < 0.05) and higher self-reported psychological distress tol-
erance (t(71) = - 2.67, p < 0.01). All other comparisons were
nonsignificant (see Table 1 and Fig. 1).
To identify the contribution of the relevant DT subscales to
ART receipt, a logistic regression analysis was conducted with
ART receipt as the dependent variable (0 = ART use; 1 = no
ART use) controlling for CD4 count, the only group difference
using the one-tailed test. CD4 count was entered in the first
step, and in the second step, the DIS Avoidance scale and DTS
Tolerance scale were entered. Given potential issues of col-
linearity of the two measures of DT, we examined the corre-
lation between subscales. No DIS or DTS subscales were
significantly correlated; the DIS Avoidance the DTS Tolerance
subscales that were entered into the model were uncorrelated
(r = - 0.09; p = 0.46). In the final model, both DT variables re-
mained significant after controlling for CD4 count (Table 2).
Specifically, greater avoidance of physical discomfort and
higher perceived capacity to tolerate psychological distress
reduced the likelihood of being on ART almost two-fold (DIS
Avoidance Subscale: [O.R. = 1.59, p < 0.01]; DTS Tolerance
Subscale: [O.R. = 1.84, p < 0.01]).
Discussion
The current study examined the relationship between
perceived capacity to tolerate both physical and psycholog-
ical distress and ART receipt among individuals living
with HIV/AIDS entering a large, urban substance abuse
treatment center. Results indicate that a substantial propor-
tion of the sample was not using ART at treatment entry
(39%), which is particularly problematic given recent rec-
ommendations to initiate ART earlier and across a more
widespread range of disease stages,1,2 as well as evidence
suggesting the potential utility of ART for secondary pre-
vention.3 Study hypotheses were partially confirmed. As
hypothesized, individuals who were more avoidant of
FIG. 1. Group differences in self-reported
physical and psychological DT based on
ART use. Note: *p < 0.05; **p < 0.01; DIS, Dis-
comfort Intolerance Scale (High Scores, Lower
Tolerance; Greater Avoidance); DTS, Distress
Tolerance Scale (High Scores, Higher Tolerance);
DIS Intolerance: t(71) = - 0.87, p = 0.66; DTS Ab-
sorption = t(71) = - 1.53, p = 0.25; DTS Appraisal
t(71) = 0.48, p = 0.24; DTS Regulation = t(71) = 0.51,
p = 0.64.
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physical discomfort were significantly less likely to be re-
ceiving ART; however, contrary to study hypotheses, higher
perceived capacity to tolerate psychological distress (i.e.,
being more able tolerate psychological distress) also was as-
sociated with lower likelihood of receiving ART. The only
other variable that distinguished individuals based on ART
receipt was CD4 count, such that individuals not receiving
ART had significantly higher CD4 counts. This is in line with
recent evidence demonstrating that individuals with higher
CD4 counts have increased odds and greater numbers of
ART treatment interruptions.24
The finding that higher self-reported avoidance of physical
discomfort was associated with approximately a two-fold
decrease in the likelihood of receiving ART is in line with
previous work pointing to patients’ fear of side effects being a
real barrier to ART use.8 Individuals who perceive themselves
as highly avoidant of physical discomfort may not want to
initiate or accommodate to a new treatment regimen. It is
interesting that the groups differed only on discomfort
avoidance and not actual perceived tolerance of physical dis-
comfort. This can be understood given previous research in-
dicating that discomfort avoidance, as opposed to intolerance,
is more highly associated with poor psychological outcomes;
it has been suggested that avoidance represents a more ‘‘ex-
treme reaction’’ then intolerance, as avoidant individuals do
not even enter a potentially uncomfortable scenario.21
High self-reported psychological DT also was associated
with approximately a two-fold decrease in the likelihood of
receiving ART. This is contrary to the directionality of previ-
ous findings that that low levels of self-reported psychological
DT are problematic for ART adherence, substance use, and
other poor outcomes.13–15 One explanation of this finding is
that individuals with high psychological DT may be more
able to deal with distress of inevitable disease progression
without appropriate medical treatment. Although counter-
intuitive, this is in line with the idea of ‘‘distress over-
tolerance,’’ which suggests that high psychological DT may be
maladaptive when individuals tolerate a high degree of dis-
tress ‘‘in a manner that does not fit with long-term values or
interests.’’25 In the present study, individuals with high levels
of psychological DT may have been more likely to tolerate the
uncertainty and distress of an inevitably worsening health
status, which may be associated with a delay in initiating or
re-initiating ART. However, these conclusions are speculative
and require further empirical attention and replication. Ad-
ditionally, study findings suggest that appraisal of, degree of
absorption by, and regulation of distress are not as strongly
related to ART receipt as is actual perceived tolerance of dis-
tress; however, these findings also need to be replicated,
particularly incorporating a multi-method, behavioral mea-
surement of DT.
Findings should be interpreted in light of study limitations,
including reliance on self-reported measurement of key study
variables, cross-sectional design, effects with relatively low
magnitude, and a small sample size. Yet, it is worth noting
that the population targeted—low-income, largely African
American substance users living with HIV—are difficult to
recruit and are at very high risk for poor HIV outcomes and
continued transmission; thus, even recruiting a small sample
cross-sectionally in this population has important public
health implications. Although also a strength of the current
study, the fact that the current sample was comprised of al-
most exclusively African American individuals—with ap-
proximately half of the sample being female and three-fourths
of the sample identifying as heterosexual—generalizability of
findings to other HIV-infected individuals, such as Caucasian
men who have sex with men or nonsubstance-using patients
should be done with caution.7 Finally, the study assessment
was limited in that it did not distinguish between individuals
who were ART naı̈ve vs. had discontinued ART. This is an
important distinction that must be made in future replications
of this work. The assessment also did not include duration of
ART use or a more comprehensive behavioral assessment of
DT. Next steps include replicating the current findings using a
larger sample size, prospective design, and more compre-
hensive, multi-method assessment of ART use and DT.
Despite these limitations, current findings have important
clinical implications, including the need to focus on psycho-
logical barriers to ART receipt, substance abuse treatment as a
clinical setting to identify individuals not receiving ART, and
the potential utility of physical and psychological DT mea-
sures as screening tools for mechanisms underlying lack of
ART receipt among substance users. Additionally, future in-
tervention efforts aimed at increasing ART use may consider
targeting one’s capacity for facing and tolerating physiolog-
ical and psychological distress associated with initiating and
persisting with an ART regimen, for instance, using accep-
tance-based approaches that target avoidance of uncomfort-
able thoughts, feelings, and/or bodily sensations.26 If
findings continue to replicate, DT may be an important in-
tervention target for increasing ART use among difficult to
reach, low-income African American substance users living
with HIV/AIDS.
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